By John Carroll All that smoke hovering around a prospective Nycomed buyout cleared early this morning as Japan’s Takeda announced it had wrapped a $13.7 billion deal for the Swiss biotech. The acquisition gives Takeda immediate entry into some key emerging markets. And the private equity owners at Nycomed break away with a new, independent …
By John Carroll Orexigen has finally inked a deal on its weight-loss drug Contrave, accepting a relatively small $50 million upfront payment and more than a billion dollars in potential milestones from Japan’s Takeda in exchange for North American marketing rights for a therapy that’s about four months away from the FDA’s finish line. Orexigen’s …
By John Carroll Faced with the looming loss of patent protection on Actos, the world’s top-selling diabetes drug, Japan’s Takeda has mapped out a drug development strategy that relies heavily on a new generation of therapies for “lifestyle diseases.” And with the ranks of the world’s overweight adults projected to grow 75 percent in the …
